Linked Life Data

9066044

Source:http://linkedlifedata.com/resource/pubmed/id/9066044

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1997-6-5
pubmed:abstractText
A modified trivalent enhanced potency IPV (E-IPV) containing trypsin-treated PV3/Saukett as the type 3-component (TryIPV) was evaluated in preclinical and Phase I and Phase II clinical trials with the regular E-IPV as a control. In Balb/c mice, TryIPV-induced antibodies targeted outside the trypsin-sensitive antigenic site, as expected. Immunogenicity of TryIPV in man, as judged by a booster response in neutralizing antibodies to type 1, 2 or 3 poliovirus, was as good as that of the regular E-IPV in both adults and children. In children the preimmunization titres of antibodies neutralizing the trypsin-treated PV3/Saukett were significantly lower than those for the untreated virus. Both vaccines induced a striking increase of antibody titres to both virus preparations. No significant harmful effects were observed. We conclude that the pilot vaccine is suitable for further evaluation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
237-43
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Immunogenicity of a pilot inactivated poliovirus vaccine with trypsin-treated type 3-component.
pubmed:affiliation
Enterovirus Laboratory, National Public Health Institute, Helsinki, Finland.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Clinical Trial, Phase II, Clinical Trial, Phase I